Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1002/ppul.21160 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Rituximab-Induced Hypersensitivity Pneumonitis in Multiple Sclerosis: A Rare Phenomenon.
Ann Indian Acad Neurol
December 2024
Department of Neurology, National Institute of Mental Health and Neurosciences, Bengaluru, Karnataka, India.
Interstitial lung disease presents with varying characteristics in patients with non-Hodgkin lymphoma undergoing rituximab-containing therapies.
Ann Hematol
September 2024
Department of Respiratory and Critical Care Medicine, Aerospace Center Hospital, Beijing, 100049, China.
Article Synopsis
- This study looked at a type of lung disease caused by a medicine called rituximab in patients with non-Hodgkin lymphoma.
- Researchers analyzed data from 321 patients to understand what kinds of lung problems they had and how to treat them.
- They found different types of lung issues and discovered many germs like bacteria and viruses that could be causing these problems, helping doctors know how to better care for these patients.
Rituximab-to-vaccine interval on SARS-CoV-2 immunogenicity in children: The potential role of prior natural infection.
Pediatr Allergy Immunol
May 2024
Unit of Immunology, Vaccinology and Rheumatology, Division of General Pediatrics, Department of Pediatrics, Gynecology and Obstetrics, Geneva University Hospitals, Geneva, Switzerland.
Background: Treatment with anti-CD20 antibodies (rituximab) is used in both adults and children to treat various autoimmune and oncological diseases. Rituximab depletes B CD20+ cells and, thereby, antibody response to vaccines. This study aimed to examine the antibody response to mRNA-based COVID-19 vaccines in children aged 5-18 years undergoing rituximab treatment compared to healthy matched children.
View Article and Find Full Text PDFA Rare Presentation of Concomitant Lung Disease and Hepatitis After Rituximab Treatment: A Case Report.
Cureus
May 2023
Hematology and Oncology, Henry Ford Health System, Detroit, USA.
Rituximab (RTX) is a chimeric monoclonal antibody that is a standard component of treatment for all B-cell malignancies. The most common adverse events related to RTX are infusion-related reactions, such as fever, chills, urticaria, flushing, and headaches. However, RTX-induced lung disease (RTX-ILD) is a rare but potentially fatal adverse reaction, and diagnosing RTX-ILD is challenging, especially when accompanied by other rare adverse reactions, such as hepatitis.
View Article and Find Full Text PDFRituximab-Induced Immune Dysregulation Leading to Organizing Pneumonia, Bronchiectasis, and Pulmonary Fibrosis.
Cureus
February 2023
Internal Medicine, Al-Quds University, Jerusalem, PSE.
We present a case of rituximab-induced organizing pneumonia (OP) along with bronchiectasis and pulmonary fibrosis, in a patient with a history of granulomatosis with polyangiitis (GPA), on long-term maintenance therapy with rituximab. T-cell dysregulation and B-cell depletion associated with the chronic use of rituximab often lead to a profound immunosuppressed state with hypogammaglobulinemia and unbalanced T-cell response. This acquired immunodeficient state with severe immune dysregulation predisposed this patient to recurrent pulmonary infection and ultimately led to bronchiectasis and pulmonary fibrosis.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!